Table 3. Clinical trials with MEK1/2 inhibitors in metastatic pancreatic cancer.
| Agent | Line of Therapy | Phase of Study | Partial Remission (PR) | Comment | Reference |
|---|---|---|---|---|---|
| Trametinib + Gemcitabine | 1st Line | Randomized Phase II | 17/77 (22%);(includes one complete remission | PR 14/77 (18%) in placebo + gemcitabine arm | Infante et al, 2014 [28] |
| Trametinib + Gemcitabine | Mixed | Phase Ib | 3/11 (27%) | Two patients had received prior therapy | Infante et al, 2013 [61] |
| Trametinib | Refractory | Phase I | 2/26 (8%) | Infante et al, 2012 [27] | |
| Selumetinib vs. Capecitabine | 2nd Line | Phase II | 2/38 (5%) | Bodoky et al, 2011 [26] | |
| XL-518 / GDC-0973 + GDC-0941 (PI3K) | Refractory | Phase Ib | 1 PR | Patient with PR had a BRAF mutation | LoRusso et al, 2012 [62] |
| CI-1040 | 1st Line | Phase II | 0/15 (0%) | Rinehart et al, 2004 [63] | |
| CI-1040 | Refractory | Phase I | 1/6 (17%) | LoRusso et al, 2005 [64] |